852. Preclinical models of non dopaminergic antipsychotics
Abstract Background Current antipsychotic treatments primarily rely on dopamine D2 receptor antagonism and show limited efficacy for negative and cognitive symptoms, as well as in treatment-resistant schizophrenia. Trace amine-associated receptor 1 (TAAR1) agonists represent a promising non-dopaminergic approach with a...